DCM
JAZZ icon

Dean Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Dean Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.1M Hold
21,156
– – 1.85% 1
2026
Q1 		$4M Sell
21,156
-2
-0% -$350 1.66% 6
2025
Q4 		$3.6M Buy
21,158
+654
+3% +$100K 1.53% 9
2025
Q3 		$2.7M Hold
20,504
– – 1.05% 23
2025
Q2 		$2.18M Buy
20,504
+4,012
+24% +$436K 0.89% 38
2025
Q1 		$2.05M Buy
16,492
+366
+2% +$47.7K 0.89% 34
2024
Q4 		$1.99M Buy
16,126
+2,108
+15% +$248K 0.85% 39
2024
Q3 		$1.56M Buy
+14,018
New +$1.54M 0.66% 85
2024
Q2 		– Sell
-11,889
Closed -$1.43M – 114
2024
Q1 		$1.43M Hold
11,889
– – 0.83% 62
2023
Q4 		$1.46M Buy
11,889
+1,928
+19% +$241K 0.9% 50
2023
Q3 		$1.29M Buy
+9,961
New +$1.33M 0.97% 35

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dean Capital Management's JAZZ Position: Q2 2026 in Review

Dean Capital Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 21,156 shares worth $5.1M. The position accounts for 1.85% of the portfolio, ranked #1.

Dean Capital Management first reported a position in JAZZ in Q3 2023 and has held it in 11 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Dean Capital Management held 21,156 shares of Jazz Pharmaceuticals worth $5.1M as of Q2 2026.
  • Dean Capital Management left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up 1.85% of Dean Capital Management's portfolio in Q2 2026, its #1 holding.
  • Dean Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Dean Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.